Pharmaceuticals and methods for treating hypoxia and screening methods therefor
US6855510B2 · kind B2 · utility
22Cited by
1References
54Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Mar 19, 2002 |
| Grant date | Feb 15, 2005 |
| Priority date | — |
| Expiry date | Jul 23, 2022 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2500/20
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Light-generating fusion proteins having a ligand binding site and a light-generating polypeptide moiety and their use as diagnostics, in drug screening and discovery, and as therapeutics, are disclosed. The light-generating fusion protein has a feature where the bioluminescence of the polypeptide moiety changes upon binding of a ligand at the ligand binding site. Tie ligand may be, for example, an enzyme present in an environment only under certain conditions, e.g., ubiquitin ligase in a hypoxic state, such that the light-generating fusion protein is “turned on” only under such conditions.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.